SEARCH

SEARCH BY CITATION

References

  • 1
    Nomenclature, diagnostic criteria and diagnostic methodology for diseases of the liver and biliary tract. Fogarty International Center Proceedings No. 22. U.S. Government Printing Office, 1976: 111.
  • 2
    Schalm S W, Summerskill W H J, Gitnick G L et al. Contrasting features and responses to treatment of severe chronic active liver disease with and without hepatitis B antigen. Gut 1976: 17: 781786.
  • 3
    Soloway R D, Summerskill W H J, Baggenstoss A H et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972: 63: 820833.
  • 4
    Cook G C, Mulligan R., Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971: 40: 159185.
  • 5
    Murray-Lyon I M, Stern R B, William R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973: 1: 735737.
  • 6
    Berk P D, Jones E A, Plotz P H et al. Corticosteroid therapy for chronic active hepatitis. Ann Intern Med 1976: 85: 523525.
  • 7
    Wright E C, Seeff L B, Berk P D et al. Treatment of chronic active hepatitis. An analysis of three controlled trials. Gastroenterology 1977: 73: 14221430.
  • 8
    Kassirer J P, Parker S G. The toss-up. N Engl J Med 1981: 305: 14671469.
  • 9
    Mistilis S P, Lam K C. Treatment of chronic active hepatitis. Aust N Z J Med 1980: 10: 6468.
  • 10
    Editorial. Immunosuppressive therapy of chronic active hepatitis. Lancet 1978: ii: 507508.
  • 11
    Editorial. Chronic active hepatitis. Br Med J 1980: 281: 258259.
  • 12
    Schlichting P., Fauerholdt L., Christensen E. et al. Prednisone treatment of chronic liver disease. I. Chronic aggressive hepatitis as a therapeutic marker. Liver 1982: 2: 104112.
  • 13
    Schalm S W, Summerskill W H J. Treatment of cirrhosis with prednisone. N Engl J Med 1975: 292: 10301031.
  • 14
    Schlichting P., Fauerholdt L., Christensen E., et al. Prednisone and chronic liver disease. II. Clinical versus morphological criteria for selection of patients for prednisone treatment. Liver 1982: 2: 113118.
  • 15
    Degos F., Degott C., Erlinger S. Inefficiency of steroid therapy in chronic active hepatitis with cholestasis. Gastroenterol Clin Biol 1980: 4: 246250.
  • 16
    Hodges J R, Millward-Sadler G H, Wright R. Chronic active hepatitis: the spectrum of disease. Lancet 1982: i: 550552.
  • 17
    Dudley F J, Scheuer P J, Sherlock S. Natural history of hepatitis-associated antigen-positive chronic liver disease. Lancet 1972: ii: 13881393.
  • 18
    Lam K C, Lai C L, Ng RP et al. Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Engl J Med 1981: 304: 380386.
  • 19
    Schalm S W, Heijting R A. Controlled observations on the long-term effect of leukocyte interferon therapy in HBsAg-positive chronic active hepatitis. Gastroenterology 1981: 80: 1347.
  • 20
    Schalm S W, Heijting R A. Temporary disappearance of viral replication in HBsAg-positive severe chronic active hepatitis. J Infect Dis 1981: 144: 282.
  • 21
    Sagnelli E., Maio G., Felaco F M et al. Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet 1980: ii: 395397.
  • 22
    Summerskill W H J, Korman M G, Ammon H V et al. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975: 16: 876883.
  • 23
    Schalm S W. Was lässt sich für die Behandlung der HBsAg-positiven chronischen Hepatitis mit Steroiden oder immunsuppressiven Arzneimitteln sagen? Internist 1979: 20: 185187.
  • 24
    Powell L W, Axelsen E. Corticosteroids in liver disease: studies on the biological conversion of prednisone to prednisolone, and plasma protein binding. Gut 1972: 13: 690696.
  • 25
    Schalm S W, Summerskill W H J, Go V L W. Prednisone for chronic active liver disease: pharmocokinetics, including conversion to prednisolone. Gastroenterology 1977: 72: 910913.
  • 26
    Mistilis S P, Schiff L. Steroid therapy in chronic hepatitis. Arch Intern Med 1964: 113: 5462.
  • 27
    Lesesne H R, Grisham J W, Fallon H J. Chronic active hepatitis: a double-blind, randomized trial of prednisolone-azathioprine versus prednisolone-placebo. Gastroenterology 1976: 71: 918.
  • 28
    Tage-Jensen U., Schlichting P., Aldershvile J. et al. Azathioprine versus prednisone in nonalcoholic chronic liver disease. Liver 1982: 2: 95103.
  • 29
    Uribe M., Schalm S W, Summerskill W H J et al. Effect of liquid diet on serum protein binding and prednisolone concentrations after oral prednisone. Gastroenterology 1976: 71: 362364.
  • 30
    Tanner A R, Gaffin J A, Halliday J W et al. Concurrent administration of antacids and prednisone: effect on serum levels of prednisolone. Br J Pharmacol 1979: 7: 397400.
  • 31
    Schalm S W, Ammon H V, Summerskill W H J. Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res 1976: 8: 221227.
  • 32
    Petereit L B, Meikle A W. Effectiveness of prednisolone during phenytoin therapy. Clin Pharmacol Ther 1978: 22: 912916.
  • 33
    Czaja A J, Ludwig J., Baggenstoss A H et al. Corticosteroid-treated chronic active hepatitis in remission. Uncertain prognosis of chronic persistent hepatitis. N Engl J Med 1981: 304: 59.
  • 34
    Kirk A P, Jain S., Pocock S. et al. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980: 21: 7883.
  • 35
    Lebrec D., Poynard T., Hillon P. et al. Propanolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis. N Engl J Med 1981: 305: 13711374.